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ABSTRACT - Purpose. Emergence of carbapenem-resistant Acinetobacter baumannii (CRAB) and their 
prolonged presence in burn units increases the risk of acquisition of CRAB.  Methods. From November 2012 to 
September 2013, 1474 burn patients were screened for CRAB isolates through testing susceptibility to 
imipenem and its comparators meropenem, and doripenem. Furthermore, the in vitro activity of other antibiotics 
against CRAB was investigated.  Results. Three patients were infected with carbapenem-susceptible A. 
baumannii (CSAB) and 168 were infected with CRAB. Approximately one-fifth (n=32) of CRAB isolates were 
obtained from patients hospitalized in Burn Intensive Care Unit (BICU). Most of CRABs were isolated from 
wound. The mean length of stay (LOS) in hospital prior to A. baumannii isolation was significantly higher for 
CRAB compared to CSAB cases (P=0.04). Amongst the independent variables, percentage of total burn surface 
area (TBSA) significantly increased the mortality rate using multivariate logistic regression (P=0.001, OR= 
16.5; 95% CI: 4.72-57.7). The majority of tested isolates were resistant to imipenem (94.8%), and to its 
comparators, doripenem (97.7%), and meropenem (97.7%). The susceptibility of CRAB isolates was less than 
10% to all tested antibiotics except for colistin (100%), doxycycline (61.9%), gentamicin (18.5%), and 
tigecycline (11.9%).  Conclusion. Resistance to carbapenem reduces the number of effective antibiotics. The 
coordinated and intensive efforts of healthcare personnel are required to meet the challenge of dissemination of 
CRAB.  Keywords. Carbapenem-susceptible A. baumannii, burn, imipenem 
 
This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For Readers”) may 
comment by clicking on ABSTRACT on the issue’s contents page. 
  
 
INTRODUCTION 
 
Acinetobacter baumannii which was initially 
described as an opportunistic bacterium of low 
pathogenicity, has evolved to a major pathogen 
especially in critical care settings during the last 
decades (1). Emergence of resistant A. baumannii 
has attracted the attention of clinicians to the strains 
capable of escaping the biocidal action of 
antibiotics and to their potential risks (2).  
 Carbapenems such as imipenem, meropenem, 
doripenem but not ertapenem are the agents of 
choice for treatment of infections caused by A. 
baumannii, when other antibiotics are not effective 
(3). Carbapenems have been used as the last-line 
drugs for the treatment of A. baumannii infections 
until 1991 when the first carbapenem-resistant 
Acinetobacter baumannii (CRAB) was recognized 
(4, 5). Over the years, the increasing number of 
CRAB strains have been documented worldwide in 
hospital- and community acquired infections (6). 
Recent studies revealed that carbapenem-resistant 
Acinetobacter spp. are more predominant in the 
Latin America, Middle East, and Asia-pacific than 
in North America or Europe (7). 
 A. baumannii strains are becoming major 
pathogen   in   healthcare-associated   infections, 
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mainly in critically ill patients (8). Burn patients are 
extremely susceptible individuals to infections 
during hospitalization and are also at risk of 
infection through their own microbiota. Factors 
predisposing burn patients to infections include the 
changes in the physical barriers such as loss of skin 
as the first line defense followed by creation of 
favorable environment for bacteria multiplication, 
increased rate of antibiotic use in burn units, and 
use of invasive devices (9). Burn wounds are sterile 
in early hours after injury but the wounds are 
frequently colonized with the circulating bacteria in 
healthcare environment (10, 11).  
 A. baumannii has emerged as predominant 
bacteria in burn patients with most of its strains 
previously eradicated by carbapenems (12). 
However, the emergence of CRAB and their 
presence for prolonged periods in burn units has 
increased the risk of acquisition of CRAB strains 
which consequently impede the successful 
treatment of affected burn patients. In this study, the 
burn patients were screened for CRAB strains 
through testing susceptibility to imipenem and its 
comparators meropenem, and doripenem. 
Furthermore, the in vitro activity of other antibiotics 
against CRAB was investigated. 
 
METHODS 
 
Materials 
The microbiologic media Blood agar base, 
MacConkey's agar, Hugh and Leifson’s medium, 
Mueller-Hinton agar, and Mueller-Hinton Broth 
were purchased from Merck (Darmstadt, Germany). 
Oxidase disk and all antibiotics disks were 
purchased from Mast Group Ltd (Bootle, UK). API 
20NE system was obtained from bioMerieux 
(Marcyl'Etoile, France). The antibiotic salts or base 
were procured from Sigma-Aldrich Co. (St Louis, 
MO, USA).  
 
Setting 
The study proposal was approved by the local 
ethical committee of Tehran University of Medical 
Sciences. Informed consent was obtained prior to 
sample collection which was performed according 
to standard protocols. Motahari Brun Center is a 
tertiary referral center located in Tehran, Iran, that 
has intensive care facilities and provides 
comprehensive care for children and adults 
suffering from burn injuries. This center houses 
burn patients who have minor to life-threatening 
injuries. Initially, all patients are admitted to 
Emergency Unit (EU) before, depending on the age, 
gender, and extent/severity of burn, they are 
directed to different units including Burn Intensive 
Care Unit (BICU), Pediatrics, Burn 1, and Burn2. In 
addition, this center has operating rooms designed 
for burn surgery. When all available beds are 
occupied, the admitted patients have to stay in the 
EU. BICU is restricted to critically ill patients 
suffering from complications of severe burns. 
Pediatrics unit is designated to children younger 
than 12 years of age, Burn1 to adult women and 
Burn2 to adult men. 
 Motahari Bun Center team members are 
strictly adhered to infection control and cross-
transmission prevention measures and are 
experienced in the management of burn wounds. 
For all patients, first aids begin immediately upon 
admission and patients benefit from initial treatment 
followed by daily treatment, advanced treatment of 
complex wounds, and rehabilitation therapy. In this 
center, the core measures are resuscitation with 
balanced electrolyte solutions, cleansing and 
debridement of wound, regular dressing of wound, 
prescribing of topical mupirocin as well as silver 
sulfadiazine as prophylactic agents, and showering 
hydrotherapy.  
 A total of 1474 burn cases referred to 
Motahari Brun Center from November 2012 to 
September 2013 were screened for CRAB. Cases 
with CRAB were patients from whom a CRAB 
isolate was recovered at least once; cases with 
CSAB were patients with carbapenem-susceptible 
A. baumannii (CSAB), the other cases were 
negative for A. baumannii. Demographic 
characteristics and medical histories were collected 
from the information recorded in medical ﬁles. The 
obtained data were: age, gender, unit of admission, 
isolation site, length of stay (LOS) in hospital prior 
to A. baumannii isolation, type of burn injury, 
percentage of total burn surface area (%TBSA), 
depth of burn injury, use of invasive devices, and 
mortality rate during hospitalization.  
 
Isolates and Identification 
All clinical samples submitted for microbiological 
examination were plated onto blood agar and 
MacConkey’s agar and incubated at 37° C. After 
the growth, colonies suspected for A. baumannii 
were identified through a combination of colony 
J Pharm Pharm Sci (www.cspsCanada.org) 19(3) 339 - 348, 2016 
 
 
 
 
341 
morphology, growth at 44°C, and biochemical tests 
such as oxidase, dextrose oxidation in Hugh and 
Leifson’s medium, and API 20NE system 
(bioMerieux, France). Confirmatory identification 
of the isolates was performed by PCR amplification 
of blaOXA-51-like gene using specific primers (13).  
  
Antimicrobial Susceptibility Testing 
 
Disk Diffusion  
For each clinical isolate of A. baumannii, 
susceptibility to imipenem (10 µg), meropenem (10 
µg), and doripenem (10 µg) was determined by disk 
diffusion method according to the Clinical and 
Laboratory Standards Institute (CLSI) guidelines 
(14). For all the antibiotic-impregnated paper disks, 
the concentrations of antibiotics were based on base 
antibiotic. Imipenem and meropenem susceptibility 
was determined according to breakpoints defined by 
CLSI. However, in the case of doripenem, the US 
Food and Drug Administration (FDA) breakpoints 
were used (15). CRAB and CSAB were defined as 
resistance and susceptibility, respectively, to both 
imipenem and meropenem; strains with 
intermediate susceptibility were considered as 
resistant/non-susceptible. The susceptibility of 
CRAB and CSAB was assessed against other 
antibiotics include colistin sulphate (25 µg), 
tigecycline (15 µg), trimethoprim-sulfamethoxazole 
(25 µg), ceftazidime (30µg), cefepime (30 µg), 
aztreonam (30 µg), gentamicin (10 µg), 
piperacillin/tazobactam (110 µg), ciprofloxacin (5 
µg), levofloxacin (5 µg), doxycycline (30 µg), 
gatifloxacin (5 µg), ceftriaxone (30 µg), amikacin 
(30 µg), tetracycline (30 µg), and cefotaxime (30 
µg). Because no tigecycline breakpoints for A. 
baumannii were recommended by the CLSI, the 
disk diffusion breakpoints of ≥16 and ≤12 mm were 
considered as susceptible and resistant, respectively 
(16). Escherichia coli ATCC 25922 and 
Pseudomonas aeruginosa ATCC 27853 strains 
were used as quality control for the susceptibility 
tests. 
 
Broth Microdilution 
Minimum inhibitory concentration (MICs) for 
imipenem, ceftazidime, gentamicin, and 
ciprofloxacin were determined by broth 
microdilution method using Cation-Adjusted 
Mueller-Hinton Broth (CAMHB). An initial 
bacterial suspension was prepared by suspending 3-
5 single colonies in 0.9% saline equivalent to 0.5 
MacFarland standard. The suspension was diluted 
1:100 in CAMHB and 100 µl of this suspension 
was inoculated to each well of microplates. The 
final concentration of inoculums was 5×10
5
 
CFU/ml. The inoculated microplates were 
incubated at 35 ±2°C in ambient air for 18–24 
hours. The following antibiotics with two-fold 
dilutions were tested: imipenem monohydrate (0.5, 
1, 2, 4, 8, 16, 32, 64, 128, and 256 µg/ml), 
ceftazidime pentahydrate (4, 8, 16, 32, 64, 128, 256, 
and 512 µg/ml), gentamicin sulphate (4, 8, 16, 32, 
64, 128, 256, and 512 µg/ml), and ciprofloxacin 
base (0.5, 1, 2, 4, 8, 16, 32, 64, 128, 256, and 512 
µg/ml) (14).  
 
Statistical Analysis 
Data analysis was performed using SPSS version 
18.0 (SPSS Inc., USA). Descriptive results were 
shown as frequencies, mean, mode, and quantiles. 
To evaluate the 95% Confidence Interval (CI) of 
quantiles, Bootstrap method with 5000 samples was 
used. For comparison of the categorical variables, 
Chi-square and Fisher’s exact tests of non-
parametric data were used. For continuous 
variables, the Mann-Whitney test was used. In 
CRAB cases, the impact of percentage of TBSA on 
mortality was estimated in terms of odds ratio 
(ORs) with 95% CI using a Backward Wald 
elimination of variables in multivariate logistic 
regression analysis, in which both factors of age 
and gender were included. Multiple comparisons 
between groups were conducted using the 
Benjamini and Hochberg false discovery rate (FDR) 
procedure (17). P values of less than 0.05 were 
considered as significant. 
 
RESULTS 
 
Cases 
During the study period, 172 of 1474 burn patients 
had at least a single positive culture for A. 
baumannii. Isolates were identified as A. baumannii 
by oxidase and nitrate negative but dextrose 
oxidation positive reactions and growth at 44°C. All 
of the isolates yielded a 353 base pair amplicon in 
PCR of blaOXA-51-like gene, confirming the identity of 
A. baumannii. Out of 172 A. baumannii infected 
patients, one case harboring imipenem susceptible, 
meropenem non-susceptible isolate was excluded 
from the study. The frequency of burn patients with 
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CRAB was 168 (98.2%) and only 3 (1.8%) patients 
infected with CSAB. The demographic 
characteristics and medical histories of CRAB and 
CSAB cases are illustrated in Table 1. There was no 
statistically significant difference in age, gender, 
unit of admission, isolation site, type of burn injury, 
percentage of TBSA, and mortality rate between 
two groups. Most of the CRAB isolates were 
obtained from patients hospitalized in Burn 2 
(n=73, 43.5%), followed by Burn1 (n=35, 20.8%), 
BICU (n=32, 19%), Pediatrics (n=23, 13.7%), and 
Emergency (n=5, 3%) units. However, when the 
CRAB isolates were normalized to the overall 
screened patients in each unit (Figure 1), the Burn1  
IC
U
B
ur
n1
B
ur
n2
P
ed
ia
tr
ic
s
E
m
er
ge
nc
y
0
5
10
15
20
**
 **
*
**
**
Unit
%
 o
f 
C
R
A
B
 i
s
o
la
te
s
/ 
s
c
re
e
n
e
d
 p
a
ti
e
n
ts
 
Figure 1. Frequency of carbapenem-resistant 
Acinetobacter baumannii (CRAB) isolates in 
relation to total screened patients of each unit (* P ≤ 
0.05 and ** P ≤ 0.001). The error bars stand for 
95% confidence interval (CIs). 
 
 
unit had significantly higher proportion of patients 
with CRAB (13.2%, 95%CI: 9.1-17.2) in 
comparison to Burn 2 (8.3%; P=0.038, 95%CI: 6.5 
- 10.2), Pediatrics (7.7%; P=0.053, 95%CI: 4.7 -
10.7), and Emergency (0.9%; P=0.001, 95%CI: 0.1 
to 1.7) units. The number of CRAB cases ranged 
from 9 to 27 per month during the study period; one 
and a half time increase in the number of CRAB 
cases was seen in February 2013 compared to 
January 2013. The predominant anatomical site of 
isolation of bacteria in both CRAB and CSAB cases 
was wound. The mean LOS in hospital prior to 
isolation of A. baumannii was significantly higher 
for CRAB compared to CSAB cases (P=0.04). All 
three CSAB isolates were recovered from patients 
hospitalized less than 72 hours but 115 (68.5%) of 
CRAB isolates were recovered from burn patients 
hospitalized for longer than 72 hours and this 
difference was statistically significant (P=0.034). 
Among the patients who were categorized as CRAB 
cases, 34 died during stay in hospital, of whom 16 
were hospitalized in BICU (Figure 2). Thirty one 
(91.2%) of died patients had more than 30% TBSA 
whereas 3 (8.8%) had less than 30% TBSA; this 
difference reached the statistical significance 
(P=0.001). As illustrated in Figure 2, the mean of 
percentage of TBSA in patients admitted to BICU 
(58.13 ±20.96) was higher than that of Burn 2 
(28.64 ±16.8), Burn 1 (30.06 ±15.88), pediatrics 
(23.57 ±15.7), and emergency (25.6 ±22.07) units. 
Multivariate logistic regression showed that 
amongst the independent variables, the percentage 
of TBSA significantly affected the mortality rate 
(P=0.001, OR= 16.5; 95% CI: 4.72-57.7).   
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Figure 2. Percentage of total burn surface area 
(TBSA) in patients with CRAB admitted to Burn 
Intensive Care Unit (BICU) and non-BICU. The 
horizontal lines indicate mean values of %TBSA. 
Filled and unfilled shapes show died and survived 
patients during stay in hospital, respectively.  
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Table 1. Age, gender, unit of admission, site of infection, length of stay in hospital (LOS), type of burn injury, 
percentage of total burn surface area (TBSA), depth of injury, devices or  catheters, and mortality rate in burn 
patients infected by carabapenem-resistant Acinetobacter baumannii (CRAB) or carbapenem-susceptible 
Acinetobacter baumannii (CSAB). 
 
a 
Burn intensive care unit, 
b
Central venous pressure (CVP) line. 
 
 
Susceptibility of Isolates  
The susceptibility of isolates to imipenem, 
meropenem, and doripenem and antibiotype profiles 
are indicated in Table 2. The majority of tested 
isolates were resistant to imipenem (94.8%) and its 
comparators doripenem (97.7%) and meropenem 
(97.7%). The most frequent antibiotype profile was 
RRR (94.2%) which represent the resistance to 
imipenem, meropenem, and doripenem, 
respectively. As indicated in Table 3, susceptibility  
of CRAB isolates was less than 10% to all tested 
antibiotics except for colistin (100%), doxycycline 
(61.9%), gentamicin (18.5%), and tigecycline 
(11.9%). One hundred sixty five (98.8%) of CRAB 
isolates were resistant to both ciprofloxacin and 
levofloxacin, and only 2 (1.2%) of ciprofloxacin-
resistant isolates showed intermediate susceptibility 
to levofloxacin. Among 94 tetracycline-resistant 
CRAB isolates, 11 (11.7%) and 36 (38.3%) were 
susceptible to tigecycline and doxycycline, 
respectively. In addition, 52 out of 82 (63.4%) 
tigecycline resistant CRAB isolates were 
susceptible to doxycycline.  
 The MIC ranges, MIC50, and MIC90 of 
imipenem, ceftazidime, gentamicin, and 
ciprofloxacin against CRAB isolates are shown in 
Table 4. 
Characteristic CRAB 
n=168 
CSAB 
n=3 
P 
Age (years: mean±SD, range) 31.5±18.01, 1-88 18±14.42, 2-30 0.13 
Gender (n: male/female) 108/60 3/0 0.55 
Burn unit (n: BICU
a
/non-BICU) 32/136 1/2 0.47 
Anatomical site or lines (n:wound/blood/ 
urine/CVP
b
/unknown) 
 
157/7/1/2/1 
 
3/0/0/0/0 
- 
Hospital length of stay (LOS) prior to isolation of 
A. baumannii (days:mean±SD) 
7.2±6.4 2±1 0.04 
Type of burn injury –n (%) 
 Electrical 
 Thermal 
 (flash/flame/scalds/contact) 
 
15 (8.9) 
152 (89.9) 
79/37/35/0 
 
0 
3 
1/0/1/1 
 
 
1 
% Total burn surface area ( TBSA) (mean ± 
SD/range) 
 Children (n=30) 
 Adults (n=141) 
 
28.3±19.6 (3-80) 
34.93±21 (1-98) 
 
10 
57±4.2 (54-60) 
 
0.33 
Depth of burn injury 
 Second degree 
 Third degree 
 Fourth degree 
 Unknown 
 
47(28) 
108 (64.3) 
12 (7.1) 
1 (0.6) 
 
1 (33.3) 
2 (66.7) 
0 
 
 
- 
Devices 
 Urinary catheter/sond/vein catheter/ 
 ventilator/other 
 
6/113/2/31/3 
 
0/1/0/1/0 
 
- 
Mortality, n (%) 34 (20.2) 1 (33.3) 0.37 
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Table 2. Susceptibility and antibiotype profile of 172 non-repetitive isolates of Acinetobacter baumannii to 
imipenem, meropenem, and doripenem using disk diffusion method based on agency breakpoint 
 
Antibiotic Susceptible 
n (%) 
Intermediate 
n (%) 
Resistant 
n (%) 
Antibiotype profile
a
 
/ n (%) 
CLSI
b
 FDA
c
 CLSI FDA CLSI FDA RRR/ 162 (94.2) 
SSS/3 (1.7) 
IRR/ 4 (2.3) 
IRS / 1 (0.6)  
RIR / 1 (0.6) 
SRR/ 1(0.6) 
Doripenem
b
 - 4 (2.3) - - - 168 
(97.7) 
Imipenem 4 (2.3) 5 (2.9) 163 (94.8) 
Meropenem 3 (1.7) 1 (0.6) 168 (97.7) 
a 
The antibiotype profile is the susceptibility results for imipenem, meropenem , and doripenem, respectively. R, I, and S 
indicate resistant, intermediate, and susceptible respectively. 
b
 CLSI : Clinical and Laboratory Standards Institute. 
c
 FDA: 
The US Food and Drug Administration. 
 
 
DISCUSSION 
 
Infection, especially with resistant bacteria is a 
major challenge in the patients suffering from burn. 
The bacteria significantly contributed to morbidity 
and mortality of burn patients, Acinetobacter 
baumannii is an emerging opportunistic pathogen 
which is rapidly developing resistance to a wide 
range of antibiotics (18). Carbapenems were used as 
drug of choice for treating of Acinetobacter-
associated infections but their therapeutic effect is 
compromised by the emergence of CRAB (19). 
CRABs are considered as an emerging threat in 
healthcare setting particularly in acute and long-
term care facilities. As described by the 
International Network for the Study and Prevention 
of Emerging Antimicrobial Resistance, the 
emergence of carbapenem resistance in 
Acinetobacter is a global sentry event that demands 
microbiological and epidemiological interventions 
(20). Active surveillance of multi-resistant 
microorganisms such as CRAB has been 
recommended in high risk populations including 
patients of burn units (21). 
 To screen CRABs in burn patients admitted 
to the referral burn center, we conducted a cross-
sectional study in all burn units, comprising BICU 
and non-BICU. Culture of specimens for CRAB 
showed that one tenth of burn patients harboring 
CRAB. The high rate of CRAB may be related in 
part to the extensive use of antibiotics in Iran and to 
the selection of resistant variants by antibiotic 
pressure. In addition, we found that only very small 
number of A. baumannii was susceptible to both 
imipenem and meropenem; categorized as CSAB. 
This result is consistent with a study that reported 
98% carbapenem resistance in A. baumannii 
isolated from 43 burn patients in Tehran (22). 
However, higher rate of resistance to imipenem 
were obtained in our study compared to a report in 
23 burn patients showing 48.9% of non-
susceptibility to imipenem (23). This variation may 
be attributed to small number of isolates in the latter 
study.  
 This study provided evidence that infection 
with CRAB continuously occurred during an 
eleven-month period but two rises in rates of CRAB 
were seen in February and April 2013, followed by 
a decreasing trend in summer months. The point 
raises in the number of CRAB may be due to the 
failure in infection control measures and cross-
transmission between patients. We found that burn 
wound infection is the main complication in burn 
patients with CRAB and CSAB. Wounds are more 
prone to infections and are favorable sites for 
colonization of bacteria until they are closed. 
Therefore, routine wound cultures must be done as 
early as patients admitted to burn units. The mean 
LOS in the hospital prior to isolation of A. 
baumannii was significantly higher for CRAB 
compared to CSAB cases. This finding should be 
interpreted  with  caution  due  to  small  number of  
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Table 3. Susceptibility of isolates which categorized to carbapenem-resistant Acinetobacter baumannii (CRAB) 
and carbapenem-susceptible Acinetobacter baumannii (CSAB) against various classes of antibiotics.  
 
Antibiotics CRAB 
n (%) 
CSAB 
n (%) 
Aminoglycosides 
amikacin 1 (0.6) 3 (100) 
gentamicin 31 (18.5) 3 (100) 
Cephems 
cefepime 1 (0.6) 3 (100) 
cefotaxime  0 (0) 0 (0) 
ceftazidime  1 (0.6) 2 (66.7) 
ceftriaxone 0 (0) 0 (0) 
Monobactams 
aztreonam 0 (0) 0 (0) 
β-Lactam/β-lactamase  inhibitor combinations 
piperacillin/tazobactam 0 (0) 2 (66.7) 
Tetracyclines 
tetracycline 12 (7.1) 3 (100) 
doxycycline 104 (61.9) 3 (100) 
tigecycline 20 (11.9) 3 (100) 
Fluoroquinolones 
ciprofloxacin 0 (0) 3 (100) 
levofloxacin 1 (0.6) 3 (100) 
gatifloxacin 2 (1.2) 3 (100) 
Folate pathway inhibitors 
trimethoprim-sulfamethoxazole 0 (0) 2 (66.7) 
Lipopeptides 
colistin 168 (100) 3 (100) 
 
 
Table 4. Minimum inhibitory concentration (MICs) ranges, MIC50, MIC90, and mode of tested antibiotics 
against Carbapenem-Resistant Acinetobacter baumannii (CRAB) isolates (n=168) using broth microdilution 
method 
 
Antibiotic Solvent Diluent MIC50 (95% CI
a
) MIC90 (95% CI) Mode Range 
b
 
Imipenem 
monohydrate 
Phosphate 
buffer, pH 
7.2, 0.01 
mol/L  
Phosphate 
buffer, pH 
7.2, 0.01 
mol/L  
64 (8 to 64) 64 (8 to 64) 64 8-64 
Ceftazidime 
pentahydrate 
Sodium 
carbonated  
 
Water 512 (512 to 512) 512 (512 to 512)  512 4-512 
Gentamicin 
sulphate 
Water Water 256 (16 to 512) 512 (512 to 512) 512 4-512 
Ciprofloxacin 
base 
Water Water 128 (128 to 256) 512 (512 to 512) 512 2-512 
a
 CI: confidence interval. 
b 
Range indicates the minimum and maximum observed value of MIC among the 
168 isolates which defined as CRAB.  
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CSAB cases and case control studies with larger 
sample size need to be designed to understand the 
effect of LOS on acquisition of CRAB. All three 
CSABs were recovered from patients hospitalized 
less than 72 hours whereas more than half of CRAB 
were isolated from patients hospitalized more than 
72 hours; showing the probability of acquiring the 
infection in burn units of hospital. The results 
showed that the number of died cases increased 
with increasing the percentage of TBSA. The 
majority of died patients were suffering from TBSA 
of more than 30% and half of the deaths occurred in 
BICU. This death rate seems to be related to the 
status of patients admitted to such unit; mainly to 
the percentage of TBSA. While TBSA was more 
than 30%, the risk of mortality increased to more 
than 16-fold; indicating that the percentage of 
TBSA is a highly significant determinant which 
affects the mortality rate. The severity of burn and 
the requirement for long term care facilities may 
explain the high mortality rate in patients infected 
with CRAB. However, the associations between 
harboring CRAB and mortality rate is difficult to 
establish owing to other factors affecting the 
mortality rate such as percentage of TBSA. 
Infection with CRAB and having TBSA greater 
than 30% may represent a significant risk factor for 
transmission of CRAB to care facilities and to other 
patients.  
 The effect of three carbapenems was 
comparatively studied against A. baumannii isolates 
and all three carbapenems showed weak activity 
against the isolates. Doripenem and meropenem 
were equally active against isolates but imipenem 
showed a very slightly greater activity than its 
comparators. This study showed that CRAB isolates 
were resistant to all tested cephems as well as 
fluoroquinolones, monobactams, and folate 
pathway inhibitors. Amongst the fluoroquinolones, 
ciprofloxacin is available in Iran and used for 
treatment of a wide variety of infections, whereas 
levofloxacin and gatifloxacin are not available as 
easy as ciprofloxacin and rarely administered. The 
high resistance rate to levofloxacin and gatifloxacin 
may be associated with overuse of ciprofloxacin 
and cross-resistance. In addition, piperacillin 
combined with tazobactam was not effective against 
CRAB. This finding highlights the low in vitro 
activity of tazobactam as a β-lactamase inhibitor 
against CRAB. Colistin retained the most activity 
against CRAB isolates followed by doxcycline, 
gentamicin, and tigecycline. The excellent in vitro 
activity of colistin has been demonstrated 
previously by several studies but its systemic use is 
limited due to the adverse effects. The most 
common adverse effects of colistin therapy are 
nephrotoxicity, neuromuscular blockade, and 
neurotoxicity and the less common effects are 
hypersensitivity reactions, skin rash, urticaria, 
generalized itching, fever, and mild gastrointestinal 
disorders (24-27). Given the high resistance rate of 
CRAB to almost all classic antibiotics, colistin 
remains as the last resort antibiotic for treatment of 
CRAB associated infections (28). To avoid the 
systemic side effects, colistin might be used 
topically as a cream that is evenly distributed over 
the burn area. Furthermore, colistin should be used 
in combination with other antibiotics to reduce the 
probability of selection of resistant variants during 
treatment (29). Use of colistin alone or in 
combination need to be guided by the results of 
clinical trials and animal models studies. Previous 
studies showed that tigecycline is an effective 
antibiotic against Gram-negative bacteria such as 
tetracycline-resistant strains (30, 31). For A. 
baumannii, no standard susceptibility breakpoint of 
tigecycline is recommended by the CLSI but based 
on the study of Jones et al. (16), we have found that 
while most of the CRAB isolates were resistant to 
tigecycline, they remained susceptible to 
doxycycline. These data indicate that emerging 
resistance to tigecycline has been occurred in these 
isolates, despite that tigecycline is not routinely 
applied for treatment of infections in our 
community. On the other hand, doxycycline was 
found to be active against CRAB, suggesting a 
potentially valuable antibiotic for treatment of 
infections caused by CRAB.  
 In the present study, the MIC50 and MIC90 
values for imipenem and ceftazidime were similar 
while the MICs of ciprofloxacin and gentamicin 
that inhibited the growth of 90% (MIC90) of isolates 
was higher than their MIC50. Considering the 
breakpoints recommended by the CLSI (2012), an 
isolate with the MIC value ≥ 16 µg/mL was 
categorized as imipenem resistant. More than 90% 
of isolates tested here, had MIC of 64 µg/mL. A 
significantly higher proportion of the isolates were 
inhibited at MIC values of 64 μg/ ml of imipenem. 
The considerably high MICs for imipenem are of 
prime importance, as the imipenem or its 
comparators are the last-line antibiotics for the 
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treatment of A. baumannii-associated infections. 
The MIC values of imipenem and ciprofloxacin 
against the isolates in this study was also similar to 
those previously reported (32-35). These results 
indicate that the MIC values of tested antibiotics are 
high, thereby, indicating that most of CRAB might 
be also multidrug resistant.  
 
CONCLUSION AND RECOMMENDATION 
 
The current study depicts the presence of high 
number of carbapenem-resistant A. baumannii in 
burn units. The resistance to carbapenem reduces 
the number of effective antibiotics. CRAB 
associated infection is a great concern in burn units 
particularly in patients with higher percentage total 
burn surface area and a challenge for physicians in 
the treatment and control of such infections. For 
patients suffering from infections caused by CRAB 
strains, the available therapeutic options are limited. 
The eradication of CRAB isolates may not be 
feasible in burn units. Hence, coordinated and 
intensive efforts of healthcare personnel are 
required for management of CRAB. Early detection 
of CRAB at the admission time, monitoring for 
CRAB during hospitalization, and testing the 
susceptibility of CRAB to other antibiotics need to 
be routinely performed . These surveillance based 
information provide a guide for clinical therapy 
decisions and may help clinicians to restrict the use 
of carbapenems in high risk patients harboring 
CRAB, to cautiously prescribe the antibiotics, and 
to adopt infection control measures in order to 
lessen the transmission of CRAB in burn units.   
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